From April 1, 2022 to June 30, 2022, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 21,587,509 shares, representing 2.07% for CNY 280.92 million under the buyback announced on December 28, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.64 CNY | -2.08% | -3.95% | +21.72% |
05-08 | CR Double-Crane Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride Injection | MT |
04-26 | CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+21.72% | 3.2B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 600062 Stock
- News China Resources Double-Crane Pharmaceutical Co.,Ltd.
- Tranche Update on China Resources Double-Crane Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 28, 2021.